{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:56:05Z","timestamp":1790916965027,"version":"4.1.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) poses a major therapeutic challenge, with loss of radioiodine avidity, limited treatment options, and worse outcomes. Current risk stratification systems were not designed to predict RAIR transformation before clinical refractoriness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective two-center study included a development cohort of 302 consecutive patients and an external validation cohort of 122. Candidate predictors were restricted to baseline demographic, clinicopathological, molecular, and biochemical variables available at or before first postoperative RAI administration; all post-treatment, response-related, and time-dependent variables were excluded\n                      <jats:italic>a priori<\/jats:italic>\n                      . Six machine-learning algorithms were developed with repeated cross-validation and compared by discrimination, probability accuracy, and clinical utility. Model interpretation used SHapley Additive exPlanations (SHAP). External transportability was assessed by discrimination, calibration, decision-curve analysis, and validation of prespecified risk groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-six patients (15.2%) developed RAIR-DTC in the development cohort and 18 (14.8%) in the external cohort. Random forest was selected for the most favorable balance of cross-validated discrimination and probability accuracy, despite comparable external discrimination from XGBoost and the stacked ensemble. It achieved an area under the receiver operating characteristic curve (AUC) of 0.896 and Brier score of 0.078 in the internal test cohort, with robust external discrimination (AUC, 0.892; PR-AUC, 0.597; sensitivity, 0.778; specificity, 0.798). Raw external calibration was poor (calibration slope 0.304; observed-to-expected ratio 0.613), indicating that ranking was preserved whereas absolute risk estimates required local recalibration. SHAP analysis identified age \u226555 years, TERT promoter (TERTp) mutation, vascular invasion, initial stimulated thyroglobulin (sTg), and extrathyroidal extension (ETE) as the dominant contributors. Training-derived quantile cut points generated three-tier risk groups, identifying a low-risk subgroup with zero events in the external cohort and a low event rate (3.3%) in the internal test set, while enriching the high-risk subgroup to event rates of 75.0% and 37.2%, respectively, with 95% confidence intervals of 47.6%-92.7% and 23.0%-53.3%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>An explainable, leakage-aware random forest based exclusively on routinely available baseline variables provided robust external discrimination and clinically meaningful early risk stratification for RAIR-DTC. Preserved discrimination did not guarantee transportable probability estimates, underscoring that external calibration and site-specific recalibration are essential prerequisites for responsible clinical deployment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1952443","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:40:30Z","timestamp":1790916030000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["An explainable and leakage-aware machine learning model for early risk stratification of radioiodine-refractory differentiated thyroid cancer: development and single-center geographic external validation"],"prefix":"10.3389","volume":"17","author":[{"given":"Gongxun","family":"Tan","sequence":"first","affiliation":[{"name":"Department of Geriatrics, Affiliated People\u2019s Hospital of Jiangsu University","place":["Zhenjiang, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Shuyang Hospital of Chinese Traditional Medicine","place":["Shuyang, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenwei","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Laboratory, Affiliated Fourth People\u2019s Hospital of Jiangsu University","place":["Zhenjiang, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canhong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Affiliated People\u2019s Hospital of Jiangsu University","place":["Zhenjiang, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Shuyang Hospital of Chinese Traditional Medicine","place":["Shuyang, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingquan","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Shuyang Hospital of Chinese Traditional Medicine","place":["Shuyang, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xu","sequence":"additional","affiliation":[{"name":"Nanjing D.A. Medical Laboratory","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated People\u2019s Hospital of Jiangsu University","place":["Zhenjiang, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated People\u2019s Hospital of Jiangsu University","place":["Zhenjiang, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lele","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohua","family":"Li","sequence":"additional","affiliation":[{"name":"Nanjing Tianyinshan Hospital, The Affiliated Hospital of China Pharmaceutical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Affiliated People\u2019s Hospital of Jiangsu University","place":["Zhenjiang, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-018-0080-7","article-title":"Thyroid surgery for differentiated thyroid cancer: recent advances and future directions","volume":"14","author":"Wang","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07222-1","article-title":"Chinese management guidelines for radioiodine-refractory differentiated thyroid cancer (2025 edition)","volume":"52","author":"Lin","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B4","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(14)60421-9","article-title":"Sorafenib in radioiodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-14-2915","article-title":"Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib","volume":"21","author":"Rothenberg","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0102","article-title":"Updated American Joint Committee on Cancer\/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (Eighth edition): what changed and why","volume":"27","author":"Tuttle","year":"2017","journal-title":"Thyroid"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac721","article-title":"Evaluating disease-specific survival prediction of risk stratification and TNM systems in differentiated thyroid cancer","volume":"108","author":"van Velsen","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg7125","article-title":"TERT accelerates BRAF mutant-induced thyroid cancer dedifferentiation and progression by regulating ribosome biogenesis","volume":"9","author":"Yu","year":"2023","journal-title":"Sci Adv"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.180240","article-title":"TERT promoter mutation predicts radioiodine-refractory character in distant metastatic differentiated thyroid cancer","volume":"58","author":"Yang","year":"2017","journal-title":"J Nucl Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.930180","article-title":"Predictive value of clinical and pathological characteristics for metastatic radioiodine-refractory differentiated thyroid carcinoma: a 16-year retrospective study","volume":"13","author":"Chai","year":"2022","journal-title":"Front Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxz041","article-title":"From development to deployment: dataset shift, causality, and shift-stable models in health AI","volume":"21","author":"Subbaswamy","year":"2020","journal-title":"Biostatistics"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2026.1891291","article-title":"Dynamic phenotyping of radioiodine-refractory differentiated thyroid cancer: thyroglobulin trajectories, dual-modal imaging, and genotype-defined treatment resistance","volume":"17","author":"Tan","year":"2026","journal-title":"Front Endocrinol"},{"key":"B16","article-title":"A unified approach to interpreting model predictions","volume":"30","author":"Lundberg","year":"2017","journal-title":"Adv Neural Inf Process Syst"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2012.0081","article-title":"Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels","volume":"22","author":"Leboulleux","year":"2012","journal-title":"Thyroid"},{"key":"B18","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12916-019-1466-7","article-title":"Calibration: the Achilles heel of predictive analytics","volume":"17","author":"Van Calster","year":"2019","journal-title":"BMC Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/ede.0b013e3181c30fb2","article-title":"Assessing the performance of prediction models: a framework for traditional and novel measures","volume":"21","author":"Steyerberg","year":"2010","journal-title":"Epidemiology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s12630-009-9041-x","article-title":"A simple method to adjust clinical prediction models to local circumstances","volume":"56","author":"Janssen","year":"2009","journal-title":"Can J Anaesth"},{"key":"B21","doi-asserted-by":"publisher","first-page":"111330","DOI":"10.3390\/cancers13102436","article-title":"Radiomics in thyroid cancer: a systematic review","volume":"172","author":"Cao","year":"2024","journal-title":"Eur J Radiol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1952443\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:40:38Z","timestamp":1790916038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1952443\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":21,"alternative-id":["10.3389\/fendo.2026.1952443"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1952443","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"article-number":"1952443"}}